YARS2

Across TCGA pan-cancer cohorts, YARS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YARS2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher YARS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated YARS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where YARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	19	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.793	.005	12	view →
LUAD	OS	Median	All	0.570	0.831	.017	9	view →
GBM	OS	Quartile	All	0.906	0.716	.004	8	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YARS2–CCRCC (OS)

Open the CCRCC breakdown →